Synopsis
Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04686-y In a phase 1b study that included an open-label and randomized-controlled cohorts of allogeneic hematopoietic cell transplantation recipients, treatment with the investigational, cultivated, multi-strain bacterial oral live biotherapeutic product, SER-155, was found to have a similar safety profile to placebo and resulted in fewer bloodstream infections, indicating further clinical investigation of this therapeutic is warranted.
The publisher’s own description. This is a short summary, not the full story, and may omit important detail.
Read the full story at Nature Medicine ↗
